{"title":"诱导多能干细胞来源的中脑类器官同种外源性移植到帕金森大鼠黑质的有效性和安全性评估","authors":"Xin Zheng, Jianwei Chen, Zhengzheng Huang, Youcheng Zhang, Liping Zhou","doi":"10.1002/btm2.70014","DOIUrl":null,"url":null,"abstract":"Current ectopic implantation has shown limited efficacy in promoting reinnervation of the nigrostriatal pathway, which is critically affected in Parkinson's disease (PD). Homotopic transplantation, on the other hand, may facilitate physiological cell rewiring of the basal ganglia, potentially improving PD symptoms. This study aimed to evaluate the efficacy and safety of homotopically engrafting human induced pluripotent stem cells (hiPSCs)‐derived midbrain organoids into the substantia nigra of PD rats. A rat model of PD was induced using 6‐hydroxydopamine (6‐OHDA) and homotopically transplanted into the lesioned SN with hiPSC‐derived hMOs. The engrafted hMOs survived and continually mature in host brains, and were mainly differentiated into dopaminergic lineage neurons, part of which presented TH<jats:sup>+</jats:sup> fibers. Behavioral evaluation demonstrated that transplantation of hMOs gradually reverse the motor disorder caused by 6‐OHDA lesioning by 22% at week 5 and 35% by week 10 post‐transplantation, respectively. No tumor formation or migration was detected in either subcutaneous space or vital organs following 10 weeks implantation. These findings support the efficacy and safety of homotopical hMOs transplantation, offering a promising cell‐based strategy for treating Parkinson's disease.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"11 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety assessment of homotopical transplantation of iPSCs‐derived midbrain organoids into the substantia nigra of Parkinsonian rats\",\"authors\":\"Xin Zheng, Jianwei Chen, Zhengzheng Huang, Youcheng Zhang, Liping Zhou\",\"doi\":\"10.1002/btm2.70014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Current ectopic implantation has shown limited efficacy in promoting reinnervation of the nigrostriatal pathway, which is critically affected in Parkinson's disease (PD). Homotopic transplantation, on the other hand, may facilitate physiological cell rewiring of the basal ganglia, potentially improving PD symptoms. This study aimed to evaluate the efficacy and safety of homotopically engrafting human induced pluripotent stem cells (hiPSCs)‐derived midbrain organoids into the substantia nigra of PD rats. A rat model of PD was induced using 6‐hydroxydopamine (6‐OHDA) and homotopically transplanted into the lesioned SN with hiPSC‐derived hMOs. The engrafted hMOs survived and continually mature in host brains, and were mainly differentiated into dopaminergic lineage neurons, part of which presented TH<jats:sup>+</jats:sup> fibers. Behavioral evaluation demonstrated that transplantation of hMOs gradually reverse the motor disorder caused by 6‐OHDA lesioning by 22% at week 5 and 35% by week 10 post‐transplantation, respectively. No tumor formation or migration was detected in either subcutaneous space or vital organs following 10 weeks implantation. These findings support the efficacy and safety of homotopical hMOs transplantation, offering a promising cell‐based strategy for treating Parkinson's disease.\",\"PeriodicalId\":9263,\"journal\":{\"name\":\"Bioengineering & Translational Medicine\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioengineering & Translational Medicine\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1002/btm2.70014\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/btm2.70014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Efficacy and safety assessment of homotopical transplantation of iPSCs‐derived midbrain organoids into the substantia nigra of Parkinsonian rats
Current ectopic implantation has shown limited efficacy in promoting reinnervation of the nigrostriatal pathway, which is critically affected in Parkinson's disease (PD). Homotopic transplantation, on the other hand, may facilitate physiological cell rewiring of the basal ganglia, potentially improving PD symptoms. This study aimed to evaluate the efficacy and safety of homotopically engrafting human induced pluripotent stem cells (hiPSCs)‐derived midbrain organoids into the substantia nigra of PD rats. A rat model of PD was induced using 6‐hydroxydopamine (6‐OHDA) and homotopically transplanted into the lesioned SN with hiPSC‐derived hMOs. The engrafted hMOs survived and continually mature in host brains, and were mainly differentiated into dopaminergic lineage neurons, part of which presented TH+ fibers. Behavioral evaluation demonstrated that transplantation of hMOs gradually reverse the motor disorder caused by 6‐OHDA lesioning by 22% at week 5 and 35% by week 10 post‐transplantation, respectively. No tumor formation or migration was detected in either subcutaneous space or vital organs following 10 weeks implantation. These findings support the efficacy and safety of homotopical hMOs transplantation, offering a promising cell‐based strategy for treating Parkinson's disease.
期刊介绍:
Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.